Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn D Crater

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Respiratory Disease|March 2, 2022
Lung deposition of inhaled once-daily long-acting muscarinic antagonists <i>via</i> standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary diseaseGlenn D Crater, Karmon Johnson, Jonathan Ward, et al.
Respiratory Medicine|March 20, 2012
Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapyAnand A Dalal, Manan Shah, Anna O D'Souza, et al.
The Open Respiratory Medicine Journal|January 22, 2011
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary diseaseAndras Koser, Jan Westerman, Sanjay Sharma, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 24, 2020
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day StudyThomas M Siler, Edmund J Moran, Chris N Barnes, et al.
Diabetes, Obesity & Metabolism|November 9, 2023
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b studyGlenn D Crater, Karine Lalonde, François Ravenelle, et al.
Therapeutic Advances in Respiratory Disease|February 29, 2020
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trialsSanjay Sethi, James F Donohue, Gary T Ferguson, et al.
The American Journal of Managed Care|September 27, 2012
Outcomes associated with timing of maintenance treatment for COPD exacerbationAnand A Dalal, Manan B Shah, Anna O D'Souza, et al.
Chest|April 29, 2020
Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different InhalersChris N Barnes, Donald A Mahler, Jill A Ohar, et al.
BMC Pulmonary Medicine|May 13, 2020
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysisJames F Donohue, Edward Kerwin, Chris N Barnes, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Respiratory Disease|March 2, 2022
Lung deposition of inhaled once-daily long-acting muscarinic antagonists <i>via</i> standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary diseaseGlenn D Crater, Karmon Johnson, Jonathan Ward, et al.
Respiratory Medicine|March 20, 2012
Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapyAnand A Dalal, Manan Shah, Anna O D'Souza, et al.
The Open Respiratory Medicine Journal|January 22, 2011
Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary diseaseAndras Koser, Jan Westerman, Sanjay Sharma, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 24, 2020
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day StudyThomas M Siler, Edmund J Moran, Chris N Barnes, et al.
Diabetes, Obesity & Metabolism|November 9, 2023
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b studyGlenn D Crater, Karine Lalonde, François Ravenelle, et al.
Therapeutic Advances in Respiratory Disease|February 29, 2020
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trialsSanjay Sethi, James F Donohue, Gary T Ferguson, et al.
The American Journal of Managed Care|September 27, 2012
Outcomes associated with timing of maintenance treatment for COPD exacerbationAnand A Dalal, Manan B Shah, Anna O D'Souza, et al.
Chest|April 29, 2020
Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different InhalersChris N Barnes, Donald A Mahler, Jill A Ohar, et al.
BMC Pulmonary Medicine|May 13, 2020
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysisJames F Donohue, Edward Kerwin, Chris N Barnes, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Pageof 2